咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Serum resistin and the risk fo... 收藏

Serum resistin and the risk for hepatocellular carcinoma in diabetic patients

作     者:Mona Mohamed Ibrahim Abdalla 

作者机构:Department of Human BiologySchool of MedicineInternational Medical UniversityBukit Jalil 57000Kuala LumpurMalaysia 

出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))

年 卷 期:2023年第29卷第27期

页      面:4271-4288页

核心收录:

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主  题:Hepatocellular carcinoma Resistin Insulin resistance Obesity Diabetes Liver cancer 

摘      要:Hepatocellular carcinoma(HCC),the predominant type of liver cancer,is a major contributor to cancer-related fatalities across the globe.Diabetes has been identified as a significant risk factor for HCC,with recent research indicating that the hormone resistin could be involved in the onset and advancement of HCC in diabetic individuals.Resistin is a hormone that is known to be involved in inflammation and insulin resistance.Patients with HCC have been observed to exhibit increased resistin levels,which could be correlated with more severe disease stages and unfavourable prognoses.Nevertheless,the exact processes through which resistin influences the development and progression of HCC in diabetic patients remain unclear.This article aims to examine the existing literature on the possible use of resistin levels as a biomarker for HCC development and monitoring.Furthermore,it reviews the possible pathways of HCC initiation due to elevated resistin and offers new perspectives on comprehending the fundamen-tal mechanisms of HCC in diabetic patients.Gaining a better understanding of these processes may yield valuable insights into HCC’s development and progression,as well as identify possible avenues for prevention and therapy.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分